[Recent progress in radioimmunodetection for cancer using radio-labeled monoclonal antibodies].
The concept of injecting anti-tumor antibodies to localize tumors was first introduced in experimental systems by Pressman (1957). Since then, various trials for tumor detection have been performed using anti-tumor antibodies. In 1970's, the radioimmunodetection of cancer has rapidly developed by the use of radioantibodies to oncofetal proteins such as CEA, AFP and hCG. Recently, there are papers dealing with animal studies of external scanning by the monoclonal antibodies that bind selectively to tumor cells derived from murine teratocarcinoma, human malignant melanoma, human mammary carcinoma and human osteosarcoma. As clinical trials the radiolabeled monoclonal antibodies against CEA or AFP were also used for the radioimmunodetection in patients with CEA or AFP-producing tumors, and the positive rates of the scanning ranged from 40 to 94%. Various related problems are also discussed.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002850:Chromatography, Gel; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000175:diagnosis* / Q000276:immunology; D000509:alpha-Fetoproteins / Q000032:analysis
D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D000509:alpha-Fetoproteins